CLINICAL TRIALS PROFILE FOR STRATTERA
✉ Email this page to a colleague
All Clinical Trials for STRATTERA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00174226 ↗ | Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar | Completed | Pfizer | Phase 2 | 2004-11-01 | Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone |
| NCT00181766 ↗ | Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS) | Completed | Eli Lilly and Company | Phase 4 | 2003-12-01 | This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the treatment of adults with attention deficit hyperactivity disorder not otherwise specified. The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day, whichever is less) in adults with ADHD NOS will be safe and well tolerated. |
| NCT00181766 ↗ | Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS) | Completed | Massachusetts General Hospital | Phase 4 | 2003-12-01 | This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the treatment of adults with attention deficit hyperactivity disorder not otherwise specified. The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day, whichever is less) in adults with ADHD NOS will be safe and well tolerated. |
| NCT00181948 ↗ | Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy | Completed | Eli Lilly and Company | Phase 4 | 2004-09-01 | This will be a 6-week, unblinded study using the medication Strattera for children and adolescents with attention deficit hyperactivity disorder (ADHD) who failed to respond to an adequate trial of stimulant treatment. Specific hypotheses are as follows: Hypothesis 1: ADHD symptomatology in youth with ADHD will be responsive to Strattera treatment in the short term. Hypothesis 2: Strattera treatment (in doses of up to 120 mg/day or 1.2 mg/kg/day) in children and adolescents with ADHD will be safe and well tolerated. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for STRATTERA
Condition Name
| Condition Name for STRATTERA | |
| Intervention | Trials |
| Attention Deficit Hyperactivity Disorder | 35 |
| Attention Deficit Disorder With Hyperactivity | 7 |
| ADHD | 5 |
| Attention Deficit Hyperactivity Disorder (ADHD) | 4 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for STRATTERA
Trials by Country
Clinical Trial Progress for STRATTERA
Clinical Trial Phase
Clinical Trial Sponsors for STRATTERA
Sponsor Name
